Skip to main content
Equibles
PRTO logo

PRTO · Protara Therapeutics, Inc.

Track PRTO — free

Use PRTO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRTO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$28.15 -0.38 (-1.32%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$226.04M
Shares
59.10M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$28.15 Open$28.37 Day$28.15–28.37 Available close range$24.68–28.58 Avg vol 30d1K Last earningsMay 13, 2026 DataMar 2026–Aug 2026 Filing10-Q · Aug 11

The closing range uses available history since Mar 25, 2026; less than a full year is stored.

Up next

Next earnings call
May 13, 2028 Est · unconfirmed · in 89 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+4% holders QoQ · +26 funds added
Insider flow Distributing
Net -$882.2K over 90 days · 100% sells
Short interest Flat
No short-interest data
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
120 holders — near 3-yr high, broad support
Price context
position in its available closing range
Range low $25 Now $28 · 89% Range high $29
vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRTO
Protara Therapeutics, Inc.
this stock
$226.04M — — — —
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
120
% held
78.0%
Net QoQ
+314.3K sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
110
View
Short & Settlement
Fails to Deliver
FTD shares
104
Value
$410
As of
Jul 29, 2026
View
Smart Money
Insider Trades Net selling
Net (90d)
-$882.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$2.9M
Net income (FY)
$-57.4M
EPS diluted
$-1.34
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
11
View
Proposed Sales
Value
$882.0K
Shares
215.7K
Filed
Jun 29, 2026
View
Earnings & Events
Earnings Calls
Last call
May 13, 2026
View

Performance

5D 20D 120D MTD YTD
PRTO -1.3% +3.8% — +3.8% —
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -1.8% +0.8% — +0.8% —
Key facts CIK 1359931 CUSIP 74365U107 13F (30d) 106 filings 106 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)